Skip to main content
COAG
NASDAQ Life Sciences

Hemab Posts Q2 Loss of $24.2M, Gets FDA Nod for Phase 3 Trial

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$49.87
Mkt Cap
$2.329B
52W Low
$23
52W High
$53.61
52W Position info
117% above low
Off High info
7.0% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

COAG has more than doubled off its 52-week low of $23.

Summary

Hemab reported a Q2 net loss of $24.2 million, or $0.80 per share, alongside $457.5 million in cash. The company also received FDA endorsement to advance to a Phase 3 trial, a major regulatory milestone. This follows the Q1 report that confirmed a cash runway into 2029 and a Breakthrough Therapy designation. The Phase 3 green light materially de-risks the pipeline and could accelerate the path to market. With a market cap near $2.3 billion, the cash position provides ample funding through key clinical readouts.

At the time of this announcement, COAG was trading at $49.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $23.00 to $53.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

COAG - Latest Insights

COAG
Nov 10, 2026, 7:08 AM EST
Filing Type: 8-K
Importance Score:
7
COAG
Nov 04, 2026, 9:05 AM EST
Source: Wiseek News
Importance Score:
7
COAG
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
COAG
Aug 11, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
COAG
Aug 11, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7